Section Arrow
NKTR.NASDAQ
- Nektar Therapeutics
Quotes are at least 15-min delayed:2026/03/06 14:42 EST
Regular Hours
Last
 71.02
-1.37 (-1.89%)
Day High 
72.98 
Prev. Close
72.39 
1-M High
75.6699 
Volume 
563.64K 
Bid
71.02
Ask
71.21
Day Low
70.5 
Open
71.92 
1-M Low
34.47 
Market Cap 
2.03B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 70.11 
20-SMA 64.78 
50-SMA 49.68 
52-W High 75.6699 
52-W Low 6.48 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.83/-11.22
Enterprise Value
2.11B
Balance Sheet
Book Value Per Share
3.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
217.72M
Operating Revenue Per Share
3.15
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DAWNDay One Biopharmaceuticals21.185+8.415+65.90%-- 
IOVAIovance Biotherapeutics4.975+0.38+8.27%-- 
EDSAEdesa Biotech6.51+2.9+80.33%-- 
QNCXQuince Therapeutics0.1058+0.001+0.95%-- 
IBRXImmunityBio8.965+0.0149+0.17%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.